PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1371897
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1371897
Biodefense Market Forecasts to 2030 - Global Analysis By Product (Anthrax, Botulism, Cholera, Influenza and Other Products), Detection Device, Application, End User and By Geography
According to Stratistics MRC, the Global Biodefense Market is accounted for $16.2 billion in 2023 and is expected to reach $26.1 billion by 2030 growing at a CAGR of 7.0% during the forecast period. A system of precautions and responses put in place to guard against and address biological threats, notably those posed by biological weapons, bioterrorism, and naturally occurring infectious diseases, is referred to as "biodefense," which is short for "biological defense." The term "biodefense" refers to a broad range of initiatives, regulations, and procedures designed to protect human health, national security, and international peace and security. The goal of biodefense is to defend against dangers posed by biological agents, such as bacteria, viruses, poisons, and other microorganisms that can harm people, animals, or plants.
According to Federal Research and Development (R&D) Funding, the Department of Defense (39.3%) and the Department of Health and Human Services (27.3%) got 96.3% of the total funding obtained by eight federal agencies during the 2017 fiscal year.
Market Dynamics:
Driver:
Increasing emphasis on research and development
The building of a competent biodefense system as well as the preservation of human health both largely rely on new technology development. The on-going increase in clinical trials and increased R&D spending are two major factors fuelling the growth of the biodefense industry. For instance, a partnership agreement between Emergent Bio Solutions and the US government was signed in April 2020. The goal of this agreement was to make it easier to develop a plasma-derived treatment for COVID-19 patients. Additionally, Biomedical Advanced Research and Development Authority (BARDA), a section of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services (HHS), awarded Emergent USD to support its COVID-HIG program, one of two hyper immune development programs that Emergent announced. Hence all the initiatives on developing structured regulations and new molecules are driving the market.
Restraint:
Ethical considerations
In the subject of biodefense, which comprises attempts to safeguard public health, national security, and global stability against biological threats, such as bioterrorism and new infectious illnesses, ethical issues are of utmost importance. Policies, practices, and research in biodefense are guided by these ethical considerations, which seek to strike a balance between the requirement for readiness and morally righteous behaviour. Numerous biodefense research projects have the potential for dual use, which means they could be employed for both harmful and legitimately scientific objectives hinder the market.
Opportunity:
Beneficial government initiatives
Governments in industrialized countries take a number of actions and implement precautionary measures to be prepared to withstand these attacks. To safeguard the public, the government regularly maintains stocks of vaccines and tools for identifying biothreats. This is attributed to significant federal funding, technological advancements, and growing public awareness. The fact that major businesses are present here is also encouraging for the sector in the event of biological epidemics, the strategy aims to improve emergency response capabilities, stimulate and promote biomedical innovation, and locate and neutralize biothreats at their source. The regional biodefense market is being stimulated by these governmental actions.
Threat:
High cost
A sophisticated biodefense system, which includes research, development, stockpiling of medical countermeasures, and readiness measures, is costly to build and sustain. Programs for biodefense funding frequently face competition from healthcare and national security concerns. Moreover, dealing with a variety of biological threats and agents is part of biodefense. Creating defences against these many chemicals demands a high level of scientific and technical knowledge.
COVID-19 Impact
The COVID-19 has a big effect on the entire healthcare sector. According to an article from disaster medicine public health emergency from May 2022, the appearance of the COVID-19 pandemic has had a significant influence on people's lives as well as the stability of the economy and society. The study showed that there was a lack of testing and surveillance during the pandemic outbreak, which resulted in a widespread problem throughout the entire healthcare system. Bio threats are expected to remain challenging and significant risks to the United States and its international interests. COVID-19 consequently had an impact on the biodefense sector.
The anthrax segment is expected to be the largest during the forecast period
The anthrax segment is estimated to have a lucrative growth, because bacillus anthracis gram-positive, rod-shaped bacteria, is the source of the deadly infectious illness anthrax. Animals both domestic and wild are frequently impacted worldwide by this natural occurrence in soil. If people come into contact with diseased animals or contaminated animal products, they could become ill with anthrax. Raising awareness and ensuring that people and healthcare professionals understand the symptoms of anthrax and react correctly in the case of an outbreak or a bioterrorism incident are essential goals of public education programs are enhancing the biodefense market.
The assays segment is expected to have the highest CAGR during the forecast period
The assays segment is anticipated to witness the highest CAGR growth during the forecast period, as these are used to find, describe, and characterize biological agents and pathogens that could endanger the environment, national security, or public health, biodefense assays are specialized testing and analytical techniques. These tests are essential for monitoring, getting ready for, and responding to biological threats like bioterrorism and newly developing infectious illnesses. Mass spectrometry, flow cytometry, polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), and immunofluorescence these are a few assays that are used to identify hazards.
Region with largest share:
North America is projected to hold the largest market share during the forecast period owing to increased government initiatives and research and development in field studies are the main growth drivers of the biodefense market in North America. For instance, the National Health Security Strategy (NHSS) and National Biodefense Strategy (NBS) focused on advancing the United States health security enterprise through prevention, preparedness, response, recovery, and mitigation efforts to combat infectious disease and biological threats, according to the 2021 report from the National Association of County and City Health Officials. Moreover, The NBS and National Security Presidential Memorandum 14 also established a leadership structure and strategy to coordinate the full range of biodefense actions carried out across the U.S. Government in order to protect the American people from biological threats is driving the regions market growth.
Region with highest CAGR:
Asia Pacific is projected to have the highest CAGR over the forecast period, owing to rising R&D spending, and the growing importance of biodefense and the threat posed by dangerous biological materials that cause emergencies. Due to the presence of established facilities for the development of vaccines, Australia and Japan have two of the most developed biodefense industries in the Asia Pacific region. To prepare for future biological dangers, nations like China and India are aggressively enhancing their R&D capacities. These are the contributing factors which are propelling the biodefense market in this region.
Key players in the market:
Some of the key players profiled in the Biodefense Market include: Siga Technologies Inc., Emergent BioSolutions Inc., Ichor Medical Systems, National Resilience, Inc., Bavarian Nordic, Dynavax Technologies, Nighthawk Biosciences, Inc., XOMA Corporation Dynport Vaccine Company, Cleveland Biolabs, Ology Bioservices, Alnylam Pharmaceuticals Inc., XOMA Corporation, Altimmune Inc., Biosearch Technologies and Bruker Detection
Key Developments:
In August 2023, Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position. Additionally, Emergent will reduce operations at its facility in Canton, Massachusetts, in response to changes in the volume of U.S. government procurements of medical countermeasures.
In July 2023, SIGA Technologies, Inc. a announced that the U.S. Department of Health and Human Services exercised procurement options for the delivery of approximately $113 million worth of oral TPOXX® treatment courses and approximately $25 million worth of IV TPOXX® treatment courses.
In July 2023, Emergent BioSolutions Inc. announced that the U.S. Food and Drug Administration (FDA) has approved CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, for post-exposure prophylaxis of disease.
Products Covered:
- Anthrax
- Botulism
- Cholera
- Influenza
- Nuclear
- Smallpox
- Other Products
Detection Devices Covered:
- Assays
- Identifiers
- Samplers
- Detectors
- Triggering Devices
- Other Detection Devices
Applications Covered:
- Military
- Civilian
End Users Covered:
- Hospitals & Clinics
- Ambulatory Care Centers
- Government Institutions
- Other End Users
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Product Analysis
- 3.7 Application Analysis
- 3.8 End User Analysis
- 3.9 Emerging Markets
- 3.10 Impact of Covid-19
4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
5 Global Biodefense Market, By Product
- 5.1 Introduction
- 5.2 Anthrax
- 5.3 Botulism
- 5.4 Cholera
- 5.5 Influenza
- 5.6 Nuclear
- 5.7 Smallpox
- 5.8 Other Products
6 Global Biodefense Market, By Detection Device
- 6.1 Introduction
- 6.2 Assays
- 6.3 Identifiers
- 6.4 Samplers
- 6.5 Detectors
- 6.6 Triggering Devices
- 6.7 Other Detection Devices
7 Global Biodefense Market, By Application
- 7.1 Introduction
- 7.2 Military
- 7.3 Civilian
8 Global Biodefense Market, By End User
- 8.1 Introduction
- 8.2 Hospitals & Clinics
- 8.3 Ambulatory Care Centers
- 8.4 Government Institutions
- 8.5 Other End Users
9 Global Biodefense Market, By Geography
- 9.1 Introduction
- 9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
- 9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
- 9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa
10 Key Developments
- 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 10.2 Acquisitions & Mergers
- 10.3 New Product Launch
- 10.4 Expansions
- 10.5 Other Key Strategies
11 Company Profiling
- 11.1 Siga Technologies Inc.
- 11.2 Emergent BioSolutions Inc.
- 11.3 Ichor Medical Systems
- 11.4 National Resilience, Inc.
- 11.5 Bavarian Nordic
- 11.6 Dynavax Technologies
- 11.7 Nighthawk Biosciences, Inc.
- 11.8 XOMA Corporation
- 11.9 Dynport Vaccine Company
- 11.10 Cleveland Biolabs
- 11.11 Ology Bioservices
- 11.12 Alnylam Pharmaceuticals Inc.
- 11.13 XOMA corporation
- 11.14 Altimmune Inc.
- 11.15 Biosearch Technologies
- 11.16 Bruker Detection
List of Tables
- Table 1 Global Biodefense Market Outlook, By Region (2021-2030) ($MN)
- Table 2 Global Biodefense Market Outlook, By Product (2021-2030) ($MN)
- Table 3 Global Biodefense Market Outlook, By Anthrax (2021-2030) ($MN)
- Table 4 Global Biodefense Market Outlook, By Botulism (2021-2030) ($MN)
- Table 5 Global Biodefense Market Outlook, By Cholera (2021-2030) ($MN)
- Table 6 Global Biodefense Market Outlook, By Influenza (2021-2030) ($MN)
- Table 7 Global Biodefense Market Outlook, By Nuclear (2021-2030) ($MN)
- Table 8 Global Biodefense Market Outlook, By Smallpox (2021-2030) ($MN)
- Table 9 Global Biodefense Market Outlook, By Other Products (2021-2030) ($MN)
- Table 10 Global Biodefense Market Outlook, By Detection Device (2021-2030) ($MN)
- Table 11 Global Biodefense Market Outlook, By Assays (2021-2030) ($MN)
- Table 12 Global Biodefense Market Outlook, By Identifiers (2021-2030) ($MN)
- Table 13 Global Biodefense Market Outlook, By Samplers (2021-2030) ($MN)
- Table 14 Global Biodefense Market Outlook, By Detectors (2021-2030) ($MN)
- Table 15 Global Biodefense Market Outlook, By Triggering Devices (2021-2030) ($MN)
- Table 16 Global Biodefense Market Outlook, By Other Detection Devices (2021-2030) ($MN)
- Table 17 Global Biodefense Market Outlook, By Application (2021-2030) ($MN)
- Table 18 Global Biodefense Market Outlook, By Military (2021-2030) ($MN)
- Table 19 Global Biodefense Market Outlook, By Civilian (2021-2030) ($MN)
- Table 20 Global Biodefense Market Outlook, By End User (2021-2030) ($MN)
- Table 21 Global Biodefense Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
- Table 22 Global Biodefense Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
- Table 23 Global Biodefense Market Outlook, By Government Institutions (2021-2030) ($MN)
- Table 24 Global Biodefense Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 25 North America Biodefense Market Outlook, By Country (2021-2030) ($MN)
- Table 26 North America Biodefense Market Outlook, By Product (2021-2030) ($MN)
- Table 27 North America Biodefense Market Outlook, By Anthrax (2021-2030) ($MN)
- Table 28 North America Biodefense Market Outlook, By Botulism (2021-2030) ($MN)
- Table 29 North America Biodefense Market Outlook, By Cholera (2021-2030) ($MN)
- Table 30 North America Biodefense Market Outlook, By Influenza (2021-2030) ($MN)
- Table 31 North America Biodefense Market Outlook, By Nuclear (2021-2030) ($MN)
- Table 32 North America Biodefense Market Outlook, By Smallpox (2021-2030) ($MN)
- Table 33 North America Biodefense Market Outlook, By Other Products (2021-2030) ($MN)
- Table 34 North America Biodefense Market Outlook, By Detection Device (2021-2030) ($MN)
- Table 35 North America Biodefense Market Outlook, By Assays (2021-2030) ($MN)
- Table 36 North America Biodefense Market Outlook, By Identifiers (2021-2030) ($MN)
- Table 37 North America Biodefense Market Outlook, By Samplers (2021-2030) ($MN)
- Table 38 North America Biodefense Market Outlook, By Detectors (2021-2030) ($MN)
- Table 39 North America Biodefense Market Outlook, By Triggering Devices (2021-2030) ($MN)
- Table 40 North America Biodefense Market Outlook, By Other Detection Devices (2021-2030) ($MN)
- Table 41 North America Biodefense Market Outlook, By Application (2021-2030) ($MN)
- Table 42 North America Biodefense Market Outlook, By Military (2021-2030) ($MN)
- Table 43 North America Biodefense Market Outlook, By Civilian (2021-2030) ($MN)
- Table 44 North America Biodefense Market Outlook, By End User (2021-2030) ($MN)
- Table 45 North America Biodefense Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
- Table 46 North America Biodefense Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
- Table 47 North America Biodefense Market Outlook, By Government Institutions (2021-2030) ($MN)
- Table 48 North America Biodefense Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 49 Europe Biodefense Market Outlook, By Country (2021-2030) ($MN)
- Table 50 Europe Biodefense Market Outlook, By Product (2021-2030) ($MN)
- Table 51 Europe Biodefense Market Outlook, By Anthrax (2021-2030) ($MN)
- Table 52 Europe Biodefense Market Outlook, By Botulism (2021-2030) ($MN)
- Table 53 Europe Biodefense Market Outlook, By Cholera (2021-2030) ($MN)
- Table 54 Europe Biodefense Market Outlook, By Influenza (2021-2030) ($MN)
- Table 55 Europe Biodefense Market Outlook, By Nuclear (2021-2030) ($MN)
- Table 56 Europe Biodefense Market Outlook, By Smallpox (2021-2030) ($MN)
- Table 57 Europe Biodefense Market Outlook, By Other Products (2021-2030) ($MN)
- Table 58 Europe Biodefense Market Outlook, By Detection Device (2021-2030) ($MN)
- Table 59 Europe Biodefense Market Outlook, By Assays (2021-2030) ($MN)
- Table 60 Europe Biodefense Market Outlook, By Identifiers (2021-2030) ($MN)
- Table 61 Europe Biodefense Market Outlook, By Samplers (2021-2030) ($MN)
- Table 62 Europe Biodefense Market Outlook, By Detectors (2021-2030) ($MN)
- Table 63 Europe Biodefense Market Outlook, By Triggering Devices (2021-2030) ($MN)
- Table 64 Europe Biodefense Market Outlook, By Other Detection Devices (2021-2030) ($MN)
- Table 65 Europe Biodefense Market Outlook, By Application (2021-2030) ($MN)
- Table 66 Europe Biodefense Market Outlook, By Military (2021-2030) ($MN)
- Table 67 Europe Biodefense Market Outlook, By Civilian (2021-2030) ($MN)
- Table 68 Europe Biodefense Market Outlook, By End User (2021-2030) ($MN)
- Table 69 Europe Biodefense Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
- Table 70 Europe Biodefense Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
- Table 71 Europe Biodefense Market Outlook, By Government Institutions (2021-2030) ($MN)
- Table 72 Europe Biodefense Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 73 Asia Pacific Biodefense Market Outlook, By Country (2021-2030) ($MN)
- Table 74 Asia Pacific Biodefense Market Outlook, By Product (2021-2030) ($MN)
- Table 75 Asia Pacific Biodefense Market Outlook, By Anthrax (2021-2030) ($MN)
- Table 76 Asia Pacific Biodefense Market Outlook, By Botulism (2021-2030) ($MN)
- Table 77 Asia Pacific Biodefense Market Outlook, By Cholera (2021-2030) ($MN)
- Table 78 Asia Pacific Biodefense Market Outlook, By Influenza (2021-2030) ($MN)
- Table 79 Asia Pacific Biodefense Market Outlook, By Nuclear (2021-2030) ($MN)
- Table 80 Asia Pacific Biodefense Market Outlook, By Smallpox (2021-2030) ($MN)
- Table 81 Asia Pacific Biodefense Market Outlook, By Other Products (2021-2030) ($MN)
- Table 82 Asia Pacific Biodefense Market Outlook, By Detection Device (2021-2030) ($MN)
- Table 83 Asia Pacific Biodefense Market Outlook, By Assays (2021-2030) ($MN)
- Table 84 Asia Pacific Biodefense Market Outlook, By Identifiers (2021-2030) ($MN)
- Table 85 Asia Pacific Biodefense Market Outlook, By Samplers (2021-2030) ($MN)
- Table 86 Asia Pacific Biodefense Market Outlook, By Detectors (2021-2030) ($MN)
- Table 87 Asia Pacific Biodefense Market Outlook, By Triggering Devices (2021-2030) ($MN)
- Table 88 Asia Pacific Biodefense Market Outlook, By Other Detection Devices (2021-2030) ($MN)
- Table 89 Asia Pacific Biodefense Market Outlook, By Application (2021-2030) ($MN)
- Table 90 Asia Pacific Biodefense Market Outlook, By Military (2021-2030) ($MN)
- Table 91 Asia Pacific Biodefense Market Outlook, By Civilian (2021-2030) ($MN)
- Table 92 Asia Pacific Biodefense Market Outlook, By End User (2021-2030) ($MN)
- Table 93 Asia Pacific Biodefense Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
- Table 94 Asia Pacific Biodefense Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
- Table 95 Asia Pacific Biodefense Market Outlook, By Government Institutions (2021-2030) ($MN)
- Table 96 Asia Pacific Biodefense Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 97 South America Biodefense Market Outlook, By Country (2021-2030) ($MN)
- Table 98 South America Biodefense Market Outlook, By Product (2021-2030) ($MN)
- Table 99 South America Biodefense Market Outlook, By Anthrax (2021-2030) ($MN)
- Table 100 South America Biodefense Market Outlook, By Botulism (2021-2030) ($MN)
- Table 101 South America Biodefense Market Outlook, By Cholera (2021-2030) ($MN)
- Table 102 South America Biodefense Market Outlook, By Influenza (2021-2030) ($MN)
- Table 103 South America Biodefense Market Outlook, By Nuclear (2021-2030) ($MN)
- Table 104 South America Biodefense Market Outlook, By Smallpox (2021-2030) ($MN)
- Table 105 South America Biodefense Market Outlook, By Other Products (2021-2030) ($MN)
- Table 106 South America Biodefense Market Outlook, By Detection Device (2021-2030) ($MN)
- Table 107 South America Biodefense Market Outlook, By Assays (2021-2030) ($MN)
- Table 108 South America Biodefense Market Outlook, By Identifiers (2021-2030) ($MN)
- Table 109 South America Biodefense Market Outlook, By Samplers (2021-2030) ($MN)
- Table 110 South America Biodefense Market Outlook, By Detectors (2021-2030) ($MN)
- Table 111 South America Biodefense Market Outlook, By Triggering Devices (2021-2030) ($MN)
- Table 112 South America Biodefense Market Outlook, By Other Detection Devices (2021-2030) ($MN)
- Table 113 South America Biodefense Market Outlook, By Application (2021-2030) ($MN)
- Table 114 South America Biodefense Market Outlook, By Military (2021-2030) ($MN)
- Table 115 South America Biodefense Market Outlook, By Civilian (2021-2030) ($MN)
- Table 116 South America Biodefense Market Outlook, By End User (2021-2030) ($MN)
- Table 117 South America Biodefense Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
- Table 118 South America Biodefense Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
- Table 119 South America Biodefense Market Outlook, By Government Institutions (2021-2030) ($MN)
- Table 120 South America Biodefense Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 121 Middle East & Africa Biodefense Market Outlook, By Country (2021-2030) ($MN)
- Table 122 Middle East & Africa Biodefense Market Outlook, By Product (2021-2030) ($MN)
- Table 123 Middle East & Africa Biodefense Market Outlook, By Anthrax (2021-2030) ($MN)
- Table 124 Middle East & Africa Biodefense Market Outlook, By Botulism (2021-2030) ($MN)
- Table 125 Middle East & Africa Biodefense Market Outlook, By Cholera (2021-2030) ($MN)
- Table 126 Middle East & Africa Biodefense Market Outlook, By Influenza (2021-2030) ($MN)
- Table 127 Middle East & Africa Biodefense Market Outlook, By Nuclear (2021-2030) ($MN)
- Table 128 Middle East & Africa Biodefense Market Outlook, By Smallpox (2021-2030) ($MN)
- Table 129 Middle East & Africa Biodefense Market Outlook, By Other Products (2021-2030) ($MN)
- Table 130 Middle East & Africa Biodefense Market Outlook, By Detection Device (2021-2030) ($MN)
- Table 131 Middle East & Africa Biodefense Market Outlook, By Assays (2021-2030) ($MN)
- Table 132 Middle East & Africa Biodefense Market Outlook, By Identifiers (2021-2030) ($MN)
- Table 133 Middle East & Africa Biodefense Market Outlook, By Samplers (2021-2030) ($MN)
- Table 134 Middle East & Africa Biodefense Market Outlook, By Detectors (2021-2030) ($MN)
- Table 135 Middle East & Africa Biodefense Market Outlook, By Triggering Devices (2021-2030) ($MN)
- Table 136 Middle East & Africa Biodefense Market Outlook, By Other Detection Devices (2021-2030) ($MN)
- Table 137 Middle East & Africa Biodefense Market Outlook, By Application (2021-2030) ($MN)
- Table 138 Middle East & Africa Biodefense Market Outlook, By Military (2021-2030) ($MN)
- Table 139 Middle East & Africa Biodefense Market Outlook, By Civilian (2021-2030) ($MN)
- Table 140 Middle East & Africa Biodefense Market Outlook, By End User (2021-2030) ($MN)
- Table 141 Middle East & Africa Biodefense Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
- Table 142 Middle East & Africa Biodefense Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
- Table 143 Middle East & Africa Biodefense Market Outlook, By Government Institutions (2021-2030) ($MN)
- Table 144 Middle East & Africa Biodefense Market Outlook, By Other End Users (2021-2030) ($MN)
